BSXBoston Scientific CorporationFinished
MANDARIN (S6371)
Inoperable Hepatocellular Carcinoma
5Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.6
Announced layoffs or restructuring
Since Jul 27, 2026 · was worth 15, fading over time
Worry score5
Score over time
- Stage
- Phase 3
- Patients
- 92 (final count)
- Started
- Sep 13, 2021
- Main results expected
- Feb 13, 2026
- Fully finished
- Aug 10, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Time to progression (TTP)
Measured over: through study completion, an average of 18 months
Safety assessed within 60 days post treatment using NCI-CTCAE v5.0
Measured over: within 60 days post treatment
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- layoffs: base 15, now 4.6, since 2026-07-27, fades (half-life) · source filing
Raw record changes
- none yet
Trial ID NCT05016245 · record last updated 2026-08-12 · checked 2026-11-09 15:47 UTC